These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31624015)

  • 1. A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity.
    Beissert T; Perkovic M; Vogel A; Erbar S; Walzer KC; Hempel T; Brill S; Haefner E; Becker R; Türeci Ö; Sahin U
    Mol Ther; 2020 Jan; 28(1):119-128. PubMed ID: 31624015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A trans-amplifying RNA simplified to essential elements is highly replicative and robustly immunogenic in mice.
    Perkovic M; Gawletta S; Hempel T; Brill S; Nett E; Sahin U; Beissert T
    Mol Ther; 2023 Jun; 31(6):1636-1646. PubMed ID: 36694464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of protective immunity against influenza A/Jiangxi-Donghu/346/2013 (H10N8) in mice.
    Kuah LF; Tang LH; Sutton T; Lim JH; Sin WL; Lamirande E; Subbarao K; Lau YF
    J Gen Virol; 2017 Feb; 98(2):155-165. PubMed ID: 27983474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.
    Wei CJ; Boyington JC; McTamney PM; Kong WP; Pearce MB; Xu L; Andersen H; Rao S; Tumpey TM; Yang ZY; Nabel GJ
    Science; 2010 Aug; 329(5995):1060-4. PubMed ID: 20647428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.
    Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.
    Sun W; Kirkpatrick E; Ermler M; Nachbagauer R; Broecker F; Krammer F; Palese P
    J Virol; 2019 Jun; 93(12):. PubMed ID: 30944178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies.
    Ferrara F; Del Rosario JMM; da Costa KAS; Kinsley R; Scott S; Fereidouni S; Thompson C; Kellam P; Gilbert S; Carnell G; Temperton N
    Front Immunol; 2021; 12():661379. PubMed ID: 34108964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trans-Amplifying RNA: A Journey from Alphavirus Research to Future Vaccines.
    Yıldız A; Răileanu C; Beissert T
    Viruses; 2024 Mar; 16(4):. PubMed ID: 38675846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.
    Khurana S; Loving CL; Manischewitz J; King LR; Gauger PC; Henningson J; Vincent AL; Golding H
    Sci Transl Med; 2013 Aug; 5(200):200ra114. PubMed ID: 23986398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination.
    Kim Y; Zheng X; Eschke K; Chaudhry MZ; Bertoglio F; Tomić A; Krmpotić A; Hoffmann M; Bar-On Y; Boehme J; Bruder D; Ebensen T; Brunotte L; Ludwig S; Messerle M; Guzman C; Mandelboim O; Hust M; Pöhlmann S; Jonjić S; Čičin-Šain L
    Cell Mol Immunol; 2022 Feb; 19(2):234-244. PubMed ID: 34992275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.
    Klausberger M; Tscheliessnig R; Neff S; Nachbagauer R; Wohlbold TJ; Wilde M; Palmberger D; Krammer F; Jungbauer A; Grabherr R
    PLoS One; 2016; 11(4):e0153579. PubMed ID: 27088239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An epitope on the stem region of hemagglutinin of H1N1 influenza A virus recognized by neutralizing monoclonal antibody.
    Yan L; Wang H; Sun L; Liu Y; Sun J; Zhao X; Li Y; Xie X; Hu J
    Biochem Biophys Res Commun; 2019 Oct; 518(2):319-324. PubMed ID: 31421820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.
    Broecker F; Zheng A; Suntronwong N; Sun W; Bailey MJ; Krammer F; Palese P
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31375573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
    Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.
    Gong X; Yin H; Shi Y; He X; Yu Y; Guan S; Kuai Z; Haji NM; Haji NM; Kong W; Shan Y
    Emerg Microbes Infect; 2016 May; 5(5):e51. PubMed ID: 27222326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.